Premium
Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases
Author(s) -
Schräder N.H.B.,
Duipmans J.C.,
Molenbuur B.,
Wolff A.P.,
Jonkman M.F.
Publication year - 2019
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.17341
Subject(s) - cannabidiol , medicine , epidermolysis bullosa , analgesic , tetrahydrocannabinol , cannabinoid , opioid , dermatology , anesthesia , cannabis , psychiatry , receptor
Summary Epidermolysis bullosa ( EB ) is a genetic blistering disorder characterized by intense pain related to disease pathology and care‐based interventions. Opioid‐based therapies underpin pain care in EB ; however, they are unable to provide adequate analgesia in a significant proportion of patients. Cannabinoid‐based medicines ( CBM s) have been studied increasingly for pain conditions of various aetiologies and pose as a novel dimension for pain care in EB . We present three patients with EB who were prescribed pharmaceutical‐grade sublingually administered CBM s comprising tetrahydrocannabinol and cannabidiol. All three patients reported improved pain scores, reduced pruritus and reduction in overall analgesic drug intake.